Complete response and long‑term survival after stereotactic body radiotherapy in a patient with liver metastasis from α‑fetoprotein‑producing gastric cancer: A case report

Kanda,Tatsuo; Matsumoto,Yasuo; Nihei,Koei; Takeishi,Toshiyuki; Naito,Makoto

doi:10.3892/ol.2023.14195

Complete response and long‑term survival after stereotactic body radiotherapy in a patient with liver metastasis from α‑fetoprotein‑producing gastric cancer: A case report

Authors:
- Tatsuo Kanda
- Yasuo Matsumoto
- Koei Nihei
- Toshiyuki Takeishi
- Makoto Naito
View Affiliations

Affiliations: Department of Gastroenterology, Southern TOHOKU General Hospital, Koriyama, Fukushima 963‑8563, Japan, Department of Radiation Oncology, Niigata Cancer Center Hospital, Niigata, Niigata 951‑8566, Japan, Department of Surgery, Sanjo General Hospital, Sanjo, Niigata 955‑0055, Japan, Department of Surgery, Niigata Prefectural Kamo Hospital, Kamo, Niigata 959‑1397, Japan, Department of Pathology, Niigata Medical Center Hospital, Niigata, Niigata 950‑2022, Japan
Published online on: December 18, 2023 https://doi.org/10.3892/ol.2023.14195
Article Number: 61

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

α‑Fetoprotein (AFP)‑producing gastric carcinoma (GC) (AFPGC) is a special subtype of GC that is clinically characterized by a high incidence of liver metastasis and poor prognosis. The present study reported the case of a patient with AFPGC who showed complete response (CR) after stereotactic body radiotherapy (SBRT) for liver metastasis. A 76‑year‑old male patient underwent total gastrectomy with D2 lymph node dissection for GC. The excised tumor was diagnosed as AFPGC due to the patient's high serum AFP level (3,763 ng/ml) and AFP expression on immunohistochemistry. The patient was diagnosed with liver metastasis two months after the surgery. ¹⁸F‑fluorodeoxyglucose positron emission tomography indicated that the metastasis was a single recurrent focus. Although the patient underwent seven cycles of chemotherapy with S‑1‑based regimens, the metastatic tumor showed only a minor response despite the decrease in serum AFP levels. To realize high‑quality disease control, SBRT was performed on the liver tumor (total dose of 48 Gy in four fractions). The metastasis showed a significant response two weeks after the completion of SBRT and CR two years later. CR was sustained and the patient survived with no evidence of recurrence 62 months after the diagnosis of liver metastasis. Literature data on the efficacy of radiotherapy for liver metastasis from AFPGC remain scarce. The present case report suggests that SBRT has high efficacy for oligometastatic diseases and may be included as an indication for the treatment of liver metastasis from AFPGC.

View Figures

View References

1	Bergstrand CG and Csar B: Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 8:1741956. View Article : Google Scholar : PubMed/NCBI
2	Smith JB: Alpha-fetoprotein: Occurrence in certain malignant diseases and review of clinical applications. Med Clin North Am. 54:797–803. 1970. View Article : Google Scholar : PubMed/NCBI
3	Kodama T, Kameya T, Hirota T, Shimosato Y, Ohkura H, Mukojima T and Kitaoka H: Production of alpha-fetoprotein, normal serum proteins, and human chorionic gonadotropin in stomach cancer: Histologic and immunohistochemical analyses of 35 cases. Cancer. 48:1647–1655. 1981. View Article : Google Scholar : PubMed/NCBI
4	Ishikura H, Kirimoto K, Shamoto M, Miyamoto Y, Yamagiwa H, Itoh T and Aizawa M: Hepatoid adenocarcinomas of the stomach. An analysis of seven cases. Cancer. 58:119–126. 1986. View Article : Google Scholar : PubMed/NCBI
5	Chang YC, Nagasue N, Kohno H, Taniura H, Uchida M, Yamanoi A, Kimoto T and Nakamura T: Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol. 85:1480–1485. 1990.PubMed/NCBI
6	Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T and Kitano S: AFP-producing gastric carcinoma: Multivariate analysis of prognostic factors in 270 patients. Oncology. 65:95–101. 2003. View Article : Google Scholar : PubMed/NCBI
7	Inoue M, Sano T, Kuchiba A, Taniguchi H, Fukagawa T and Katai H: Long-term results of gastrectomy for alpha-fetoprotein-producing gastric cancer. Br J Surgery. 97:1056–1061. 2010. View Article : Google Scholar : PubMed/NCBI
8	Hirajima S, Komatsu S, Ichikawa D, Kubota T, Okamoto K, Shiozaki A, Fujiwara H, Konishi H, Ikoma H and Otsuji E: Liver metastasis is the only independent prognostic factor in AFP-producing gastric cancer. World J Gastroenterol. 19:6055–6061. 2013. View Article : Google Scholar : PubMed/NCBI
9	Tsurumachi T, Yamamoto H, Watanabe K, Honda I, Watanabe S, Yamada S, Jingu K, Satomi D and Fujita M: Resection of liver metastasis from alpha-fetoprotein-producing early gastric cancer: Report of a case. Surg Today. 27:563–566. 1997. View Article : Google Scholar : PubMed/NCBI
10	Asahi Y, Kamiyama T, Homma S, Hatanaka KC, Yokoo H, Nakagawa T, Kamachi H, Nakanishi K, Tahara M, Kakisaka T, et al: Resection of liver metastasis derived from alpha-fetoprotein-producing gastric cancer-report of 4 cases. Int Canc Conf J. 5:98–103. 2016. View Article : Google Scholar
11	Benson AB, D'Angelica MI, Abbott DE, Anaya DA, Anders R, Are C, Bachini M, Borad M, Brown D, Burgoyne A, et al: Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 19:541–565. 2021. View Article : Google Scholar : PubMed/NCBI
12	Kimura T, Fujiwara T, Kameoka T, Adachi Y and Kariya S: The current role of stereotactic body radiation therapy (SBRT) in hepatocellular carcinoma (HCC). Cancers (Basel). 14:43832022. View Article : Google Scholar : PubMed/NCBI
13	Japanese Gastric Cancer Association, . Japanese Classification of Gastric Carcinoma-2nd English Edition. Gastric Cancer. 1:10–24. 1998. View Article : Google Scholar : PubMed/NCBI
14	Fernandez LM, São Julião GP, Figueiredo NL, Beets GL, van der Valk MJM, Bahadoer RR, Hilling DE, Meershoek-Klein Kranenbarg E, Roodvoets AGH, Renehan AG, et al: Conditional recurrence-free survival of clinical complete responders managed by watch and wait after neoadjuvant chemoradiotherapy for rectal cancer in the International Watch & Wait Database: A retrospective, international, multicentre registry study. Lancet Oncol. 22:43–45. 2021. View Article : Google Scholar : PubMed/NCBI
15	Miyazaki T, Sohda M, Sakai M, Kumakura Y, Yoshida T, Kuriyama K, Yokobori T, Miyazaki M, Hirato J, Okumura T, et al: Multimodality therapy including proton beam therapy for AFP producing esophageal cancer with multiple liver metastases. Intern Med. 57:2333–2339. 2018. View Article : Google Scholar : PubMed/NCBI
16	Ajani JA, D'Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al: Gastric cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:167–192. 2022. View Article : Google Scholar : PubMed/NCBI
17	Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, Yoshikawa T, Kobayashi D, Tanaka C and Fujiwara M: Surgical resection of hepatic metastasis from gastric cancer: A review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 17:206–212. 2014. View Article : Google Scholar : PubMed/NCBI
18	Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, Yoshida Y, Hamauchi S, Todaka A, Yokota T, et al: Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 21:338–344. 2018. View Article : Google Scholar : PubMed/NCBI
19	Rusthoven KE, Kavanagh BD, Cardenes H, Stieber VW, Burri SH, Feigenberg SJ, Chidel MA, Pugh TJ, Franklin W, Kane M, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol. 27:1572–1578. 2009. View Article : Google Scholar : PubMed/NCBI
20	Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, Mulroy L, Lock M, Rodrigues GB, Yaremko BP, et al: Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 393:2051–2058. 2019. View Article : Google Scholar : PubMed/NCBI
21	Ushiku T, Shinozaki A, Shibahara J, Iwasaki Y, Tateishi Y, Funata N and Fukayama M: SALL4 represents fetal gut differentiation of gastric cancer, and is diagnostically useful in distinguishing hepatoid gastric carcinoma from hepatocellular carcinoma. Am J Surg Pathol. 34:533–540. 2010. View Article : Google Scholar : PubMed/NCBI